DK2766003T3 - Sammensætning til forebyggelse af neuropatisk smerte - Google Patents
Sammensætning til forebyggelse af neuropatisk smerte Download PDFInfo
- Publication number
- DK2766003T3 DK2766003T3 DK12769682.1T DK12769682T DK2766003T3 DK 2766003 T3 DK2766003 T3 DK 2766003T3 DK 12769682 T DK12769682 T DK 12769682T DK 2766003 T3 DK2766003 T3 DK 2766003T3
- Authority
- DK
- Denmark
- Prior art keywords
- memantine
- day
- administered
- composition
- neuropathic pain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 57
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 56
- 230000002265 prevention Effects 0.000 title claims description 5
- 229960004640 memantine Drugs 0.000 claims abstract description 95
- 238000011161 development Methods 0.000 claims abstract description 17
- 230000002980 postoperative effect Effects 0.000 claims abstract description 17
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 123
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 29
- 230000001965 increasing effect Effects 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 238000002679 ablation Methods 0.000 claims description 4
- 239000007941 film coated tablet Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 76
- 208000002193 Pain Diseases 0.000 description 39
- 230000036407 pain Effects 0.000 description 36
- 208000004454 Hyperalgesia Diseases 0.000 description 31
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 14
- 108010038912 Retinoid X Receptors Proteins 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 208000035154 Hyperesthesia Diseases 0.000 description 12
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 12
- 210000001032 spinal nerve Anatomy 0.000 description 12
- 210000005036 nerve Anatomy 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 10
- 206010053552 allodynia Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 230000006399 behavior Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002266 amputation Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000917 hyperalgesic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 102000034570 NR1 subfamily Human genes 0.000 description 2
- 108020001305 NR1 subfamily Proteins 0.000 description 2
- 102000038100 NR2 subfamily Human genes 0.000 description 2
- 108020002076 NR2 subfamily Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000146 antalgic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- KSOYGIQTLKFLTM-UHFFFAOYSA-N n-(benzenesulfonyl)-2-chloropyridine-4-carboxamide Chemical compound C1=NC(Cl)=CC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)=C1 KSOYGIQTLKFLTM-UHFFFAOYSA-N 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012034 trail making test Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- UKGGFGIPAZKIRC-UHFFFAOYSA-N 7-tert-butyl-5-(4-chlorophenyl)-6h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=C2C=NN=C2N(C(C)(C)C)CN1C1=CC=C(Cl)C=C1 UKGGFGIPAZKIRC-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 108091008644 NR2D Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical class C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940112801 mobic Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036441 nociceptive stimulation Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 208000005877 painful neuropathy Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Analgetisk sammensætning, indeholdende memantin, kendetegnet ved, at den indgives dagligt til en menneskelig patient, som skal gennemgå en kirurgisk operation, i en periode, som ligger mellem 1 dag og 42 dage forud for den kirurgiske operation, til anvendelse i forebyggelsen af udviklingen af postoperative neuropatiske smerter hos samme patient.
2. Sammensætning til anvendelse ifølge krav 1, kendetegnet ved, at den indgives i en periode, som ligger mellem 1 dag og 28 dage inden operationen af patienten.
3. Sammensætning ifølge et af de foregående krav, kendetegnet ved, at den præoperative indgivelse af sammensætningen sker i på hinanden følgende trin med stigende doser.
4. Sammensætning ifølge et af de foregående krav, kendetegnet ved, at den indgives i form af memantinhydrochlorid i en dosis, som ligger mellem 5 mg/dag og 20 mg/dag.
5. Sammensætning ifølge et af de foregående krav, kendetegnet ved, at den indgives oralt i form af filmovertrukket tablet eller drikkelig opløsning.
6. Sammensætning ifølge et af kravene 1 til 4, kendetegnet ved, at den indgives med infusion i en koncentration, som ligger mellem 5 mg/dag/kg og 20 mg/dag/kg.
7. Sammensætning til anvendelse ifølge et af de foregående krav, kendetegnet ved, at den er beregnet til at indgives i en patient, som skal gennemgå et kirurgisk indgreb, som kan medføre neuropatiske smerter, hvor det kirurgiske indgreb er udvalgt blandt ablation af et lem, en del af et lem, et or- gan eller en del af et organ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1159147A FR2980973B1 (fr) | 2011-10-11 | 2011-10-11 | Composition pour le traitement prophylactique de la douleur neuropathique. |
| PCT/EP2012/070043 WO2013053746A1 (fr) | 2011-10-11 | 2012-10-10 | Composition pour le traitement prophylactique de la douleur neuropathique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2766003T3 true DK2766003T3 (da) | 2018-03-19 |
Family
ID=47002892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12769682.1T DK2766003T3 (da) | 2011-10-11 | 2012-10-10 | Sammensætning til forebyggelse af neuropatisk smerte |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140378551A1 (da) |
| EP (1) | EP2766003B1 (da) |
| DK (1) | DK2766003T3 (da) |
| ES (1) | ES2662747T3 (da) |
| FR (1) | FR2980973B1 (da) |
| WO (1) | WO2013053746A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4395772A1 (en) * | 2021-08-31 | 2024-07-10 | Ethismos Research, Inc. | Methods of preventing and treating pain and associated symptoms |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| CA2449987C (en) * | 2001-06-07 | 2015-11-03 | Christine N. Sang | Treatment of central neuropathic pain |
| US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| RU2336062C1 (ru) * | 2007-04-23 | 2008-10-20 | Галина Ивановна Должич | Способ лечения сложного миопического астигматизма |
-
2011
- 2011-10-11 FR FR1159147A patent/FR2980973B1/fr active Active
-
2012
- 2012-10-10 US US14/350,594 patent/US20140378551A1/en not_active Abandoned
- 2012-10-10 ES ES12769682.1T patent/ES2662747T3/es active Active
- 2012-10-10 DK DK12769682.1T patent/DK2766003T3/da active
- 2012-10-10 EP EP12769682.1A patent/EP2766003B1/fr not_active Not-in-force
- 2012-10-10 WO PCT/EP2012/070043 patent/WO2013053746A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013053746A1 (fr) | 2013-04-18 |
| FR2980973A1 (fr) | 2013-04-12 |
| EP2766003A1 (fr) | 2014-08-20 |
| EP2766003B1 (fr) | 2017-12-13 |
| US20140378551A1 (en) | 2014-12-25 |
| FR2980973B1 (fr) | 2013-11-15 |
| ES2662747T3 (es) | 2018-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xie et al. | Involvement of glia in central sensitization in trigeminal subnucleus caudalis (medullary dorsal horn) | |
| Tang et al. | FGF2 attenuates neural cell death via suppressing autophagy after rat mild traumatic brain injury | |
| CA2761156C (en) | Methods of preventing ischemic injury using peripheral nociceptive stimulation | |
| WO2010099546A1 (en) | Method of reducing brain cell damage or death | |
| AU2014249530B2 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| Wamil et al. | Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons. | |
| Wang et al. | Spinal cord stimulation reduces cardiac pain through microglial deactivation in rats with chronic myocardial ischemia | |
| Liu et al. | Intrathecal administration of roscovitine prevents remifentanil-induced postoperative hyperalgesia and decreases the phosphorylation of N-methyl-D-aspartate receptor and metabotropic glutamate receptor 5 in spinal cord | |
| JP3623501B2 (ja) | インターロイキン−１阻害化合物による神経病学的状態の治療 | |
| JP2002519391A (ja) | 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用 | |
| CN101835470A (zh) | 包含缩氨基脲和缩氨基硫脲的药物组合物和治疗炎症、疼痛和发热病症和防止炎症体征及症状的方法 | |
| DK2766003T3 (da) | Sammensætning til forebyggelse af neuropatisk smerte | |
| Das et al. | Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain | |
| KR20170003567A (ko) | 의약으로서 사용되기 위한 (r)-펄린돌 및 약학적으로 허용 가능한 그의 염 | |
| Xiao et al. | Cathepsin S in the spinal microglia facilitates morphine-induced antinociceptive tolerance in rats | |
| Sahu et al. | A comparison of clonidine and fentanyl as an adjuvant to intrathecal bupivacaine for spinal anaesthesia and postoperative analgesia in patients undergoing caesarean section | |
| KR102573243B1 (ko) | 신경병증성 통증 치료 또는 예방용 enu 약학 조성물 | |
| CN110882240A (zh) | 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn | |
| US11446264B2 (en) | Memory manipulation via modification of protein kinase C zeta activity | |
| Steglatro | New Drug Approvals | |
| Faisal et al. | Iraqi Journal of Pharmacy | |
| Andersohn | CAPSINOIDS, NON-PUNGENT TRPV1 AGONISTS, INDUCE A MILD HYPOTHERMIA THAT PROVIDES SHORT-AND LONG-TERM NEUROPROTECTION AFTER ISCHEMIC STROKE | |
| WO2019135363A1 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
| EA050066B1 (ru) | Применение композиции, содержащей цилостазол, при получении лекарственного средства для лечения цереброваскулярных заболеваний | |
| JP2006045204A (ja) | アロディニアの治療、改善、予防剤 |